You are here: Home: YIR: Multiple Myeloma: Priority 1

PRIORITY 1 PUBLICATIONS / PRESENTATIONS ( ESSENTIAL)

 

Michele Cavo et al. Bortezomib (Velcade)-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Proc ASH 2007.

S Vincent Rajkumar et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus lowdose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. Proc ASH 2007.

Paul Richardson et al. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): Preliminary results of a phase 1/2 study. Proc ASH 2007.

Sundar Jagannath et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21(1):151-7.

Asher Alban Chanan-Khan et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study. Blood 2007;109(6):2604-6.

Meletios Dimopoulos et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357(21):2123-32.

Donna M Weber et al; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357(21):2133-42.

Robert Z Orlowski et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression. J Clin Oncol 2007;25(25):3892-901.

Jesus F San Miguel et al. MMY-3002: A Phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Proc ASH 2007.

Jean Luc Harousseau et al. VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): Updated results of the IFM 2005/01 trial. Proc ASH 2007.

Thierry Facon et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 2007;370(9594):1209-18.
Table of Contents Top of Page